Fight Aging! Newsletter, November 14th 2022
In this study, we show that TXNIP is vital for the cell fate choice when cells are challenged by various stress signals. Furthermore, prolonged IGF1 treatment leads to the establishment of a premature senescence phenotype characterized by a unique senescence network signature. Combined IGF1/TXNIP-induced premature senescence can be associated with a typical secretory inflammatory phenotype that is mediated by STAT3/IL-1A signaling. Finally, these mechanistic insights might help with the understanding of basic aspects of IGF1-related pathologies in the clinical setting.
Investigating the Ability of Type 2 Diabetes...
Source: Fight Aging! - November 13, 2022 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Investigating the Ability of Type 2 Diabetes Treatments to Modestly Slow Aging Extends to SGLT-2 Inhibitors
There is something of a trend towards picking over the landscape of type 2 diabetes medication in search of therapies that can modestly slow aging, at least in animal models. If metformin is anything to go by, we shouldn't be at all optimistic that this will result in useful outcomes in humans. "Useful" in this context means reliable gains in late life health and life expectancy in metabolically normal people, where those gains are larger than those that can be achieved with exercise, and with minimal side-effects. Otherwise, this seems like time and effort that could be directed to more productive areas of research and de...
Source: Fight Aging! - November 8, 2022 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
Fight Aging! Newsletter, October 31st 2022
This study used mice to evaluate how their lifestyles - eating fatty foods vs. healthy and exercising vs. not - affected the metabolites of their offspring. Metabolites are substances made or used when the body breaks down food, drugs or chemicals, or its own fat or muscle tissue. "We have previously shown that maternal and paternal exercise improve health of offspring. Tissue and serum metabolites play a fundamental role in the health of an organism, but how parental exercise affects offspring tissue and serum metabolites has not yet been investigated."
Researchers used targeted metabolomics - the study of metaboli...
Source: Fight Aging! - October 30, 2022 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
More on the Debate Over the Classification of Aging as a Disease
Whether or not aging is clearly listed as a disease in the International Classification of Diseases (ICD) maintained by the World Health Organization (WHO) only matters because medical research and development is heavily regulated. Since aging isn't classified as a disease, there is no clear roadmap to obtaining regulatory approval to treat aging with a working rejuvenation therapy, and therefore no investor is willing to commit to funding that work. What happens instead is that the range of biotech companies presently working to produce age-slowing and rejuvenating therapies pick a specific age-related disease to start wi...
Source: Fight Aging! - October 26, 2022 Category: Research Authors: Reason Tags: Politics and Legislation Source Type: blogs
Repeating the Point that Metformin Just Doesn't Look Good in Animal Studies
Based on studies conducted in mice, metformin is a terrible candidate drug for the treatment of aging. It may well benefit metabolically abnormal individuals, such as diabetics, but results for aged, metabolically normal mice are all over the map. Further, the gold standard, rigorous Interventions Testing Program found no benefit in their assessment. If the goal is to modestly slow aging, then rapamycin is way and far better: robust, replicated results on health and life span in animal studies. But the goal should not be to modestly slow aging! It should be to produce rejuvenation! The sizable fraction of academia and indu...
Source: Fight Aging! - October 25, 2022 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
Fight Aging! Newsletter, October 17th 2022
This study investigated whether multimorbidity is associated with incident dementia and whether associations vary by different clusters of disease and genetic risk for dementia. The study used data from the UK Biobank cohort, with baseline data collected between 2006 and 2010 and with up to 15 years of follow-up. Participants included women and men without dementia and aged at least 60 years at baseline. The presence of at least 2 long-term conditions from a preselected list of 42 conditions was used to define multimorbidity.
A total of 206,960 participants (mean age 64.1 years) were included in the final sample, of...
Source: Fight Aging! - October 16, 2022 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
RAS/MAPK Pathway Inhibition as an Example of the Way in Which Cancer Research Informs Aging Research
A sizable number of potential approaches to slowing aging via metabolic manipulation were first tested in the cancer research community. In part, this is because that side of the research community has tested near every compound in the libraries at some point in time, but it is also the case there are deep ties between approaches that might impact cancer and changes that might slow aging. This is particularly the case in the matter of cellular senescence, of great relevance to both cancer and aging, and the first senolytic drugs to clear senescent cells had already seen some success in the cancer field. In at least one cas...
Source: Fight Aging! - October 10, 2022 Category: Research Authors: Reason Tags: Medicine, Biotech, Research Source Type: blogs
Fight Aging! Newsletter, October 10th 2022
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter,
please visit:
https://www.fightaging.org/newsletter/
Longevity Industry Consulting Services
Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - October 9, 2022 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Interventions Testing Program Results for Rapamycin and Arcabose in Combination
The Interventions Testing Program (ITP) at the National Institute on Aging (NIA) performs rigorous, expensive assessments of the ability of various (usually pharmaceutical) interventions to slow aging in mice. Conducting a study with rigor in this context means the use of large numbers of mice spread across multiple facilities, with careful control of the environment in order to minimize both known and unknown confounding factors in life span studies. Most of the interventions tested over the past twenty years of the ITP, on the basis of earlier studies suggesting that they may slow aging, in fact fail to extend life in mi...
Source: Fight Aging! - October 6, 2022 Category: Research Authors: Reason Tags: Medicine, Biotech, Research Source Type: blogs
Fight Aging! Newsletter, October 3rd 2022
In conclusion, based on the analysis of proteomics and transcriptome, we identified four SRMs that may affect aging and speculated their possible mechanisms, which provides a new target for preventing aging, especially skin aging.
A Popular Science Article on the State of Epigenetic Clocks
https://www.fightaging.org/archives/2022/09/a-popular-science-article-on-the-state-of-epigenetic-clocks/
This popular science article is a good view of the present state of development and use of epigenetic clocks, covering the issues as well as the promise. Epigenetic age can be measured, with many different clocks...
Source: Fight Aging! - October 2, 2022 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
A Small Lifespan Study of Combined Interventions
My attention was drawn recently to a small mouse life span study run by one of the groups that has been in the longevity community for a while now. It is interesting for testing combinations of interventions that have in the past been demonstrated to modestly slow aging in mice (such as rapamycin), or modestly improve aspects of cell function in old tissues (such as nicotinamide mononucleotide). Combinatorial studies are rare in academia and industry, for reasons that have a lot to do with (a) the perverse incentives produced by the existence of intellectual property, in that the rights to use specific interventions can be...
Source: Fight Aging! - September 26, 2022 Category: Research Authors: Reason Tags: Medicine, Biotech, Research Source Type: blogs
A 50 year old with chest pain? What is going on? By Emre Aslanger.
Posted by Emre Aslanger, our newest blog Editor. Emre is a distinguished cardiologist in Turkey, and has published widely on the ECG in OMI and other areas.Emre Aslanger Google Scholar ProfileA 50-year-old male with a 20 years ’ history of diabetes mellitus treated with metformin only presents with chest pain that started 20 minutes ago. The pain radiates to left inner arm and is now about to resolve. His admission ECG is given below.What do you think?You can click on it to make it larger, but let ' s make it a bit easier to see here:What do you think?(you can still click on it to make it larger)Although the wa...
Source: Dr. Smith's ECG Blog - September 25, 2022 Category: Cardiology Authors: Emre Aslanger Source Type: blogs
Fight Aging! Newsletter, September 5th 2022
Conclusion
Coupled with the animal data, and the existing human trial data for safety, the results here suggests that someone should run a formal, controlled trial of flagellin immunization in older people, 65 and over. The goal would be to see whether (a) this sort of outcome holds up in a larger group of people, and (b) there is a meaningful impact on chronic inflammation and other parameters of health that are known to be affected by the aging of the gut microbiome.
The most interesting part of the data is perhaps the decline in microbial diversity, when considered against the gains elsewhere. Microbial dive...
Source: Fight Aging! - September 4, 2022 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Searching for Age-Slowing Drugs in the Antidiabetic Portfolio
Data for the ability of metformin to slow aging has researchers looking at other antidiabetic drugs these days, even given that the evidence for metformin to have a meaningful impact on aging in non-diabetic animals is not great, very mixed, and even the human data for a modest addition of a few years in type 2 diabetes patients is most likely not as good as the impact of exercise and control of weight. Still, repurposing drugs to produce modest effects in a different condition has long been a going concern; regulators make it so hard to develop new drugs that it makes economic sense to repurpose existing drugs, even when ...
Source: Fight Aging! - August 31, 2022 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
Fight Aging! Newsletter, August 22nd 2022
In conclusion, application of a multi-species bat epigenetic clock provides strong evidence that hibernation is associated with slower epigenetic ageing. The multi-species clock explains 94% of the variation in the chronological ages of both hibernating and non-hibernating big brown bats; however, the clock estimates are equal to or greater than the chronological age, suggesting big brown bats age slightly faster than a 'typical' bat, especially during the active period. (Source: Fight Aging!)
Source: Fight Aging! - August 21, 2022 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
